TMS for OCD
Obsessive Compulsive Disorder
Commercial/Clinical DevelopmentActive
Key Facts
Indication
Obsessive Compulsive Disorder
Phase
Commercial/Clinical Development
Status
Active
Company
About Magstim
Founded in 1992, Magstim is a pioneering private company in the neurotechnology and medical device sector, with a 30+ year history. It operates a commercial-stage business model, generating revenue from the sale of its TMS, EEG, and tDCS systems to research institutions and clinical providers globally. The company's technology is clinically validated, with its TMS systems forming the basis for FDA-cleared treatments for conditions like Major Depressive Disorder (MDD). Magstim's strategy focuses on expanding clinical indications for its neuromodulation platforms and integrating its modalities for advanced brain research and therapy.
View full company profileTherapeutic Areas
Other Obsessive Compulsive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| OCD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| NBS System 6 for OCD | Nexstim | Approved |
| Obsessive Compulsive Disorder Studies | Noesis Pharma Clinical Trials | Phase 2-4 |